Navigation Links
Researchers explore the antidepressant effects of ketamine
Date:2/21/2008

Philadelphia, PA, February 21, 2008 Drug treatments for depression can take many weeks for the beneficial effects to emerge. The excruciating and disabling nature of depression highlights the urgency of developing treatments that act more rapidly. Ketamine, a drug used in general medicine as an anesthetic, has recently been shown to produce improvements in depressed patients within hours of administration. A new study being published in the February 15th issue of Biological Psychiatry provides some new insight into the mechanisms by which ketamine exerts its effects.

Ketamine is classified as an N-methyl d-aspartate (NMDA) glutamate receptor antagonist. Maeng and colleagues now provide new evidence that these antidepressant effects of NMDA receptor antagonists are mediated by their ability to increase the stimulation of -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors. In other words, their findings indicate that the antidepressant-like effects of drugs like ketamine are dependent on AMPA receptor stimulation. This suggests that drugs that enhance AMPA receptor function might have rapid antidepressant properties.

Dr. Husseini Manji, corresponding author on this paper and a Deputy Editor of Biological Psychiatry, explains that by aiming new medications at more direct molecular targets, such as NMDA or AMPA, we may be able to bypass some of the steps through which current antidepressants indirectly exert their effects a roundabout route that accounts for the long time it takes for patients to begin feeling better with the conventional medications. He adds, Todays antidepressant medications eventually end up doing the same thing, but they go about it the long way around, with a lot of biochemical steps that take time. Now weve shown what the key targets are and that we can get at them rapidly.

This study is especially important because even though this important antidepressant effect has been found in ketamine, its use also has significant drawbacks. According to John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, the only NMDA receptor antagonist found to be effective so far, ketamine, produces transient changes in perception and impairments in cognition. It is also in the same class of drugs as PCP (phencyclidine) and can cause hallucinations, among other side effects. Dr. Krystal notes that it is possible that drugs that directly enhance the activity of AMPA glutamate receptors, the AMPAkines, would have antidepressant effects similar to ketamine, without the unwanted side effects. Exploring the antidepressant effects of the AMPAkines will now be an important target for researchers.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Researchers Make Stem Cells That Secrete Insulin
2. U of M researchers determine structure of protein that mutates DNA of the AIDS virus HIV-1
3. Researchers create first chikungunya animal model
4. Researchers aim to prevent global prematurity and stillbirths
5. Researchers Aim to Prevent Global Prematurity and Stillbirths
6. UH researchers study Hispanic childrens activities, views on places to play
7. Researchers discover new way to reverse poor circulation and heal wounds
8. Bacterial toxin closes gate on immune response, Penn researchers discover
9. UD researchers discover technique for repairing gene defect that causes spinal muscular atrophy
10. Veterinary researchers study poultry virus as human cancer treatment
11. UD researchers discover promising technique for repairing gene that causes spinal muscular atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 2017 , ... The National Business Research Institute (NBRI) is ... Emergency Medical Technicians and welcomes this organization to the NBRI Circle of ... Ph.D. , CEO & Organizational Psychologist at NBRI. “This award is a result ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which ... nutrients from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... the body recognizes its raw form (unlike the synthetically made options that are on ...
(Date:4/26/2017)... Pa. (PRWEB) , ... April ... ... division, which provides an agile ecosystem and domain expertise for sponsors and ... configurable randomization and trial supply management (RTSM) software platform. Bioclinica AGILE ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 product ... for education and business. , Mirroring360 Pro enables educators, business professionals and individuals ...
(Date:4/25/2017)... ... 25, 2017 , ... A stressful work environment can hurt the physical and ... and performance in the workplace. The goal of Clearview Resolution Services has always been ... April, Clearview Resolution Services will be shutting down the office early on Fridays. The ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence that ... Parkinson,s, according to a study released today that will be ... Meeting in Boston , April 22 ... the treatment of Parkinson,s disease, the oral drug levodopa has ... and longevity. But as the disease progresses, the effects of ...
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
Breaking Medicine Technology: